The Role Of Pre-IPO Financial Indicators And Intermediaries In Aftermarket Performance And Survival In The US Biopharmaceutical Market

ASU Author/Contributor (non-ASU co-authors, if there are any, appear on document)
David Williams, Professor of Healthcare Management (Creator)
Institution
Appalachian State University (ASU )
Web Site: https://library.appstate.edu/

Abstract: This paper examines factors affecting the stock price, net proceeds, and subsequent survival of biopharmaceutical firms that have gone public between 1996 and 2007 in the USA. We find that the financial condition of biopharmaceutical firms going public has deteriorated. The results also indicate that the financial condition of the firm prior to its going public and the intermediaries associated with the firm and initial public offering have little effect on first-day price increases. The findings, however, indicate that several of these financial indicators, and having prestigious underwriters, do have a significant effect on the amount of net proceeds received by the firm.

Additional Information

Publication
Williams, D.R., Young, C.C. The Role of Pre-IPO Financial Indicators and Intermediaries in Aftermarket Performance and Survival in the US Biopharmaceutical Market. J Pharm Innov 7, 127–139 (2012). https:// doi.org/10.1007/s12247-012-9131-0. Publisher version of record available at: https://link.springer.com/article/10.1007/s12247-012-9131-0
Language: English
Date: 2012
Keywords
Initial public offering, Net proceeds, Survival

Email this document to